01/09/2020 Benralizumab, mepolizumab and omalizumab for treating severe asthma
NRThe Ministry of Health’s Drug Advisory Committee has not recommended listing:
- Benralizumab and mepolizumab on the Medication Assistance Fund (MAF) for treating severe eosinophilic asthma; and
- Omalizumab on the MAF for treating severe allergic asthma
due to unacceptable cost-effectiveness at the prices proposed by the manufacturers.